A Study of Modified Stem Cells in Traumatic Brain Injury (TBI) (STEMTRA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02416492 |
|
Recruitment Status :
Completed
First Posted : April 15, 2015
Results First Posted : December 27, 2021
Last Update Posted : December 27, 2021
|
Sponsor:
SanBio, Inc.
Information provided by (Responsible Party):
SanBio, Inc.
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The primary purpose of the clinical study is to evaluate the clinical efficacy of intracranial administration of SB623 cells on patients with chronic motor deficit from Traumatic Brain Injury. A secondary purpose of the study is 1) to evaluate the effect of intracranial administration of SB623 cells on disability parameters and 2) to evaluate the safety and tolerability of intracranial administration of SB623 cells. Patients with stable, chronic motor deficits secondary to focal traumatic brain injury must be 12 months post TBI.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Traumatic Brain Injury | Biological: SB623 cells Procedure: Sham Control | Phase 2 |
This study was a multicenter, randomized (3:1) double-blind, active and sham-surgery controlled study to evaluate the safety, tolerability, and efficacy of stereotactic intracranial injection of SB623 cells in patients with fixed motor deficits from TBI. The study was conducted at approximately 22 sites across the United States, Ukraine, and Japan.
Two groups, Group 1 and Group 2, received investigational product SB623 and sham surgery, respectively, in a 3:1 randomization scheme. Group 1 was further randomized in a 1:1:1 ratio to receive either 2.5 million, 5 million, or 10 million SB623 cells. Randomization was performed via an interactive web response system (IWRS).
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 63 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI) |
| Actual Study Start Date : | July 6, 2016 |
| Actual Primary Completion Date : | January 31, 2019 |
| Actual Study Completion Date : | March 5, 2019 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Traumatic Brain Injury
| Arm | Intervention/treatment |
|---|---|
|
Experimental: SB623 Cells
SB623 Cells: 2.5, 5 or 10 million cells
|
Biological: SB623 cells
SB623 cells will be implanted in the peri-infarct area using stereotactic surgery. |
|
Sham Comparator: Sham Surgery
Control Sham Surgery
|
Procedure: Sham Control
Sham Surgery |
Primary Outcome Measures :
- Change From Baseline in Fugl-Meyer Motor Scale (FMMS) Score at Week 24 Among All Patients [ Time Frame: 24 weeks ]The FMMS motor component consists of the 33-item upper extremity subscale (UE-FMMS) and the 17-item lower extremity subscale (LE-FMMS). Items were scored on a 3-point ordinal scale: 0= cannot perform; 1= partial motion; 2= full motion Individual items were then summed to determine scores for the 2 subscale scores, as well as a motor total score (total of all item scores including the 2 subscales UE-FMMS and LE-FMMS). As a result, the UE-FMMS subscale score ranged from 0 to 66 and the LE-FMMS subscale score ranged from 0 to 34. The FMMS motor total score ranged from 0 (hemiplegia) to a maximum of 100 points (normal motor performance).
Secondary Outcome Measures :
- Change From Baseline in Disability Rating Scale Score at Week 24 Among All Patients [ Time Frame: 24 weeks ]
DRS is an observer rated, 30-point ordinal scale that evaluates eight areas of functioning in four categories:
- Consciousness (eye opening, verbal response, motor response)
- Cognitive ability (feeding, toileting, grooming)
- Dependence on others
- Employability
Each area of functioning was rated on a scale of 0 to either 3 or 5. The maximum score is 29 (extreme vegetative state) and the minimum score is 0 (person without disability).
- Change From Baseline in ARAT Total Score at Week 24 Among Upper Extremity Deficit Patients [ Time Frame: 24 weeks ]The ARAT total score is the sum of the scores from 19 tests spread across four subscales: grasp, grip, pinch, and gross movement. Each test is scored on an ordinal 4-point scale with 0= non movement, 1 = the movement task is partially performed, 2 = the movement task is completed but takes abnormally long, and 3 = the movement is performed normally. Summation of a 0-3 score in each item yields a total score between 0 and 57.
- Change From Baseline in Gait Velocity (10 Meter Walk Time in Seconds) at Week 24 Among Lower Extremity Deficit Patients [ Time Frame: 24 weeks ]Gait Velocity was measured on a standard 10 meter walk.
- Change From Baseline in NeuroQOL T-scores at Week 24 of NeuroQOL Domains [ Time Frame: 24 weeks ]Two NeuroQoL short form assessments were used (upper extremity function and lower extremity function); each has 8 items with 5 possible scores (e.g. 1= not at all, 2=a little bit, 3= somewhat, 4=quite a bit, 5=very much) or frequency ("never"to "always"); Raw scores are converted to T-scores based on a consistent metric (i.e., the T distribution) and data from the US general population. The theoretical range in scale for Upper extremity T-score and Lower extremity T-score are 12.8 to 53.8 and 16.5 to 58.6 respectively. When interpreting these T-scores, higher scores correspond to higher levels of functioning whereas lower scores correspond to lower levels of functioning.
- Global Rating of Perceived Change: The Percentage of Subjects Scoring Either 6 or 7 on the Global Rating of Perceived Change by Both Subject and Physician [ Time Frame: 24 weeks ]
The proportions of SB623 treated subjects (pooling all SB623 doses) scoring either 7 (much better) or 6 (a little better, meaningful) on the Global Rating of Perceived Change (from Baseline) - Subject at Week 24 and on the Global Rating of Perceived Change (from Baseline) - Clinician at Week 24 was compared to the corresponding proportions of sham surgery control subjects using logistic regression models with adjustment for the baseline Fugl-Meyer Motor Scale score and the GOS-E score at screening as continuous covariates. The following 7-point Likert scale was used
- Score 7 = Much better
- Score 6 = A little better, meaningful
- Score 5 = A little better, not meaningful
- Score 4 = About the same
- Score 3 = A little worse, not meaningful
- Score 2 = A little worse, meaningful
- Score 1 = Much worse
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Documented history of TBI, with correlated MRI or CT
- At least 12 months post-TBI
- Focal cerebral injury able to be identified on MRI (+/- concomitant diffuse axonal injury)
- Neurological motor deficit substantially due to focal cerebral injury observed on MRI
- GOS-E score of 3-6 (i.e. moderate or severe disability)
- Require Motricity Index 10-81 (UE Scale) and/or 10-78 (LE Scale)
- Able and willing to undergo computed tomography (CT) and magnetic resonance imaging (MRI)
- Subjects must be willing to participate in study related exercises to the extent possible
- Able to undergo all planned neurological assessments
Exclusion Criteria:
- History or presence of any other major neurological disease
- Any seizures in the prior 3 months
- The presence of contracture at any joints that would interfere with interpretation of any of the neurological assessments (e.g. contracture preventing the detection of any increase in the range of motion or ability to perform a task)
- Other neurologic, neuromuscular or orthopedic disease that limits motor function
- Clincially significant finding on MRI of brain not related to TBI
- Known presence of any malignancy except squamous or basal cell carcinoma of the skin
- History of CNS malignancy
- Positive findings on tests for occult malignancy, unless a non-malignant etiology is confirmed
- Uncontrolled systemic illness, including, but not limited to: hypertension (systolic >150 mm Hg or diastolic >95 mm Hg); diabetes; renal, hepatic, or cardiac failure
- Uncontrolled major psychiatric illness, including depression symptoms (CESD-R Scale of ≥16)
- Unexplained abnormal preoperative test values (blood tests, electrocardiogram [ECG], chest X-ray); x-ray evidence of infection; uncontrolled atrial fibrillation or uncontrolled congestive heart failure
- Presence of craniectomy (without bone flap replacement) or other contraindication to stereotactic surgery
- Participation in any other investigational trial within 4 weeks of initial screening or within 7 weeks of study entry
- Botulinum toxin injection, phenol injection, intrathecal baclofen, or any other interventional treatments for spasticity (except bracing and splinting) 16 weeks priot to the Baseline visit.
- Ongoing use of other non-traditional drugs
- Substance use disorder (per DSM-V criteria, including drug or alcohol)
- Contraindications to head CT or MRI
- Pregnant or lactating
- Female patients of childbearing potential unwilling to use an adequate birth control method during the 12 months of the study
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02416492
Locations
Show 36 study locations
Sponsors and Collaborators
SanBio, Inc.
Investigators
| Principal Investigator: | Daniel C Lu, MD, PhD | University of California, Los Angeles, Department of Neurosurgery |
Study Documents (Full-Text)
Documents provided by SanBio, Inc.:
Documents provided by SanBio, Inc.:
Study Protocol [PDF] May 17, 2018
Statistical Analysis Plan [PDF] September 16, 2019
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | SanBio, Inc. |
| ClinicalTrials.gov Identifier: | NCT02416492 |
| Other Study ID Numbers: |
TBI-01 |
| First Posted: | April 15, 2015 Key Record Dates |
| Results First Posted: | December 27, 2021 |
| Last Update Posted: | December 27, 2021 |
| Last Verified: | November 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
Additional relevant MeSH terms:
|
Brain Injuries Brain Injuries, Traumatic Wounds and Injuries Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Craniocerebral Trauma Trauma, Nervous System |